Lack of efficacy of convalescent plasma in COVID‐19 patients with concomitant hematological malignancies: An Italian retrospective study

DOI Web Site Web Site 被引用文献1件

抄録

<jats:title>Abstract</jats:title><jats:p>A multicenter retrospective study was designed to assess clinical outcome of COVID‐19 in patients with hematological malignancies (HM) following treatment with anti‐SARS‐CoV‐2 convalescent plasma (CP) or standard of care therapy. To this aim, a propensity score matching was used to assess the role of non‐randomized administration of CP in this high‐risk cohort of patients from the Italian Hematology Alliance on COVID‐19 (ITA‐HEMA‐COV) project, now including 2049 untreated control patients. We investigated 30‐ and 90‐day mortality, rate of admission to intensive care unit, proportion of patients requiring mechanical ventilatory support, hospitalization time, and SARS‐CoV‐2 clearance in 79 CP recipients and compared results with 158 propensity score‐matched controls. Results indicated a lack of efficacy of CP in the study group compared with the untreated group, thus confirming the negative results obtained from randomized studies in immunocompetent individuals with COVID‐19. In conclusion, this retrospective analysis did not meet the primary and secondary end points in any category of immunocompromized patients affected by HM.</jats:p>

収録刊行物

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ